LBA 3A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases. (13th May 2019) - Clemons, M; Stober, C; Mates, M; Joy, A A; Robinson, A; Hilton, J; Blanchette, P; Aseyev, O; Pond, G; Fergusson, D